表紙:癌バイオマーカーの世界市場の分析
市場調査レポート
商品コード
745288

癌バイオマーカーの世界市場の分析

Global Cancer Biomarker Market -2019-2026

出版日: | 発行: DataM Intelligence | ページ情報: 英文 | 納期: 約2営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.27円
癌バイオマーカーの世界市場の分析
出版日: 2020年01月01日
発行: DataM Intelligence
ページ情報: 英文
納期: 約2営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の癌バイオマーカーの市場について分析し、市場の基本構造や最新情勢、全体的な市場動向の見通し (今後8年間分)、市場区分別 (バイオマーカー別/プロファイル技術別/用途別) および地域別の詳細動向、主な市場促進・抑制要因、市場シェア構造、主要企業のプロファイルなどについて調査しております。

第1章 分析手法・範囲

第2章 産業分析

  • 市場促進要因
  • 市場抑制要因
  • ポーターのファイブフォース分析

第3章 市場概要

  • 疫学的分析
  • 治験分析

第4章 製品パイプラインの分析

第5章 癌の症状別の市場区分

  • 肉腫
  • 大腸癌
  • 子宮頸癌
  • 肺癌
  • 乳癌

第6章 バイオマーカーの種類別の市場区分

  • タンパク質バイオマーカー
  • 遺伝子バイオマーカー
  • その他

第7章 プロファイル技術別の市場区分

  • オミクス技術
  • 細胞遺伝学
  • イムノアッセイ (免疫検定)
  • 画像技術
  • バイオインフォマティクス

第8章 用途別の市場区分

  • 創薬・薬剤開発
  • 疾患健診・診断
  • 訓練立案・リスク評価
  • その他

第9章 地域別の市場区分

  • 北米 (米国、カナダ、メキシコなど)
  • 欧州 (英国、ドイツ、スペイン、フランスなど)
  • アジア太平洋地域 (中国、日本、インド、オーストラリアなど)
  • 南米 (ブラジル、アルゼンチンなど)
  • 他の国々 (RoW)

第10章 競争環境

  • 市場参入企業
  • 主要企業が採用している主な戦略

第11章 企業プロファイル

  • AbbVie
  • Boehringer Ingelheim
  • Sanofi
  • Pfizer
  • Merck
  • GSK
  • Roche
  • Johnson and Johnson
  • AstraZeneca
  • Teva Pharmaceutical Industries

第12章 付録

目次

The global cancer biomarker market is estimated to reach a market value of USD XX billion by 2026 from an initial market value of USD 11,479.2 million in 2018. The global cancer biomarker market is forecasted to grow at a CAGR of 6.34% in the forecasted period 2019-2026.

Increasing Incidence and Cancer Prevalent Pool, Growth in Importance of Biological and Targeted Therapies, Increasing Use in Drug Development, increasing strategic alliances between the companies for the development of cancer biomarker, and growing patient awareness campaigns and programs by government, companies, and NGO's are some of the key trends in the cancer biomarker market.

Market Dynamics

According to Globocan 2012, the incidence rates of cancer types is increasing notably for many cancer types globally. The incidence of all cancer types worldwide is anticipated to increase at a CAGR of 2.5% during 2015-2030. Mortality rate of cancers is likely to increase at a higher rate compared to incidence rate during 2015-2030, at a CAGR of 2.6%. By cancer type, incidence population of lung cancer is expected to grow at a faster pace. In terms of mortality too, lung cancers have highest mortality rate, approximately one-fifth of the cancer-related deaths worldwide is due to lung cancers.

Segmentation by Biomarker Type

By biomarker type, genetic biomarker account for the largest share in the cancer biomarker market. The biomarker market is estimated to grow at nominal of pace in the forecasted period growing at a CAGR of XX% in the forecasted period 2019-2026. Genetic Biomarker is defined as a DNA or RNA characteristic that is an indicator of normal biologic processes, pathogenic processes, and/or response to therapeutic or other intervention.

Genetic mutations are the primary causes for several cancer types and thus identifying these key mutations holds significant clinical importance in drug development, cancer diagnosis and treatment.

The approval of novel gene based assays and companion diagnostics will fuel the market for genetic biomarkers in the forecast period. For instance, in January 2018, FDA has approved a PMA supplement extending the indications for use of QIAGEN's therascreen EGFR RGQ PCR Kit as a companion diagnostic to guide the use of Boehringer Ingelheim's targeted therapy GILOTRIF for first-line treatment of NSCLC.

Segmentation by Geography

North America accounts for the largest market share in the 2017 with the market being dominated by the United States. North America is dominating the cancer biomarkers market due to established R&D infrastructure and high acceptance of biomarker-based cancer testing, adequate reimbursement coverage in this region. In addition, the largest share of North America is due to the increasing government support for discovery and development of biomarkers, increasing demand for personalized medicine, high adoption of advanced omics technologies for biomarker discovery, and rising use of biomarkers in drug discovery and development by pharmaceutical companies in that region. The US holds the largest market share in North America followed by Canada due to growing research and developments in cancer biomarkers with rising number of cancer cases in this region.

On 5 December 2017, the European Cancer Patient Coalition (ECPC), in collaboration with the Member of the European Parliament Marlene Mizzi (S&D, Malta) organized an event on the topic of Cancer Biomarkers in the Era of Personalized Medicines. The European Medicines Agency has endorsed a UK-US project to use an imaging biomarker to help select Parkinson's disease patients most likely to benefit from clinical trials.

India, China, Brazil, and Australia market are growing at a higher rate while United States, Italy, Germany, Japan, and Spain market are growing at a slower rate but contribute to the largest market revenue in 2017.

Competitive Landscape

The cancer biomarker market is a highly competitive market with genetic biomarker being consolidated market while protein biomarker market being fragmented market. Companies in the industry are focusing on launching novel products into the market with partnerships being the most adopted strategy by the major companies in the industry.

Scope of the Report

Segmentation by Cancer Indication

Hematology malignancies

Prostate cancer

Sarcoma

Colorectal Cancer

Cervical Cancer

Lung Cancer

Breast Cancer

Segmentation by Biomarker Type

Protein Biomarker

Generic Biomarker

Others

Segmentation by Profiling Technologies

Omics Technologies

Cytogenetics

Immunoassays

Imaging Technologies

Bioinformatics

Segmentation by Application

Drug Discovery And Development

Disease Screening and Diagnosis

Treatment Planning & Risk Assessment

Others

The report also covers the key factors impacting the market, Porter 5 Forces, Market Share Analysis, Price trend analysis, Product Benchmarking, and company profiles.

Why Purchase the Report?

  • Visualize the composition of the global cancer biomarker market with clear distinction between each biomarker and its application
  • Identify commercial opportunities in the global cancer biomarker market analysing trends and co-development deals.
  • Excel data sheet with thousands of data points of the global cancer biomarker market
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key products of all major market players

Target Audience:

  • Equipment Suppliers/ Buyers
  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1: Methodology and Scope

  • 1.1 Research Methodology
  • 1.2 Scope of the report

2: Industry Analysis

  • 2.1 Market Drivers
  • 2.2 Market Restraints
  • 2.3 Porters Five Forces

3. Market Overview

  • 3.1 Epidemiology Analysis
  • 3.2 Clinical Trial Analysis

4. Product Pipeline Analysis

5. Segmentation by Cancer Indication

  • 5.1 Sarcoma
  • 5.2 Colorectal Cancer
  • 5.3 Cervical Cancer
  • 5.4 Lung Cancer
  • 5.5 Breast Cancer

6. Segmentation by Biomarker Type

  • 6.1 Protein Biomarkers
  • 6.2 Genetic Biomarkers
  • 6.3 Others

7. Segmentation by Profiling Technology

  • 7.1 Omics Technologies
  • 7.2 Cytogenetics
  • 7.3 Immunoassays
  • 7.4 Imaging Technologies
  • 7.5 Bioinformatics

8. Segmentation by Application

  • 8.1 Drug Discovery And Development
  • 8.2 Disease Screening and Diagnosis
  • 8.3 Treatment Planning & Risk Assessment
  • 8.4 Others

9. Segmentation by Geography

  • 9.1 North America
    • 9.1.1 United States
    • 9.1.2 Canada
    • 9.1.3 Mexico
    • 9.1.4 Rest of North America
  • 9.2 Europe
    • 9.2.1 United Kingdom
    • 9.2.2 Germany
    • 9.2.3 Spain
    • 9.2.4 France
    • 9.2.5 Rest of Europe
  • 9.3 Asia-Pacific
    • 9.3.1 China
    • 9.3.2 Japan
    • 9.3.3 India
    • 9.3.4 Australia
    • 9.3.5 Rest of Asia-Pacific
  • 9.4 South America
    • 9.4.1 Brazil
    • 9.4.2 Argentina
    • 9.4.3 Rest of South America
  • 9.5 Rest of the World

10. Competitive Landscape

  • 10.1 Market Player Analysis
  • 10.2 Key Strategies Adopted by Major companies

11. Company Profiles

  • 11.1 AbbVie
  • 11.2 Boehringer Ingelheim
  • 11.3 Sanofi
  • 11.4 Pfizer
  • 11.5 Merck
  • 11.6 GSK
  • 11.7 Roche
  • 11.8 Johnson and Johnson
  • 11.9 AstraZeneca
  • 11.10 Teva Pharmaceutical Industries

12. Appendix

  • 12.1 Disclaimer
  • 12.2 Contact Us